{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.2","upperLimit":"27.7","value":"18.6"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"11.9","value":"10.1"},{"groupId":"OG002","lowerLimit":"3.1","upperLimit":"36.5","value":"13.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"The median OS times (months) for liposarcoma, leiomyosarcoma and MFH.","dispersionType":"95% Confidence Interval","groups":[{"description":"Experimental: Sunitinib Malate (SU011248) Treatment","id":"OG000","title":"Liposarcoma Cohort Only"},{"description":"Experimental: Sunitinib Malate (SU011248) Treatment","id":"OG001","title":"Leiomyosarcoma Cohort Only"},{"description":"Experimental: Sunitinib Malate (SU011248) Treatment","id":"OG002","title":"Malignant Fibrous Histiocytoma (MFH) Cohort Only"}],"paramType":"MEDIAN","populationDescription":"All participants who completed the study","reportingStatus":"POSTED","timeFrame":"From On Treatment to Off Study - average of 6 months","title":"Participants' Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}